Question 1

What is InnoCare Pharma?

Accepted Answer

InnoCare Pharma is a Company.

Question 2

How often does InnoCare Pharma appear in global news?

Accepted Answer

Tracked across 4 news events drawn from 24 articles.

Question 3

When was InnoCare Pharma first tracked by Ergen?

Accepted Answer

First tracked on May 27, 2026.

Question 4

When was InnoCare Pharma last mentioned in news?

Accepted Answer

Last active on Aug 04, 2026.

Question 5

What is InnoCare Pharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: 68 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is InnoCare Pharma in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 4 events.

Question 7

What is the most recent event involving InnoCare Pharma?

Accepted Answer

InnoCare orelabrutinib approved Australia (May 27, 2026, 6 articles).

Question 8

How did the "InnoCare orelabrutinib approved Australia" event impact InnoCare Pharma?

Accepted Answer

InnoCare Pharma developed orelabrutinib and received approval from the Australia — Therapeutic Goods Administration (TGA) in Australia, expanding its global market presence and offering a new treatment option for Mantle Cell Lymphoma patients.

Question 9

How did the "InnoCare Doses First Patient ICP-B208" event impact InnoCare Pharma?

Accepted Answer

InnoCare Pharma announced the dosing of the first patient in a clinical trial for its novel CDH17 targeted ADC, ICP-B208, which is a significant step in its drug development pipeline and could enhance its market position in cancer treatment.

Question 10

How did the "InnoCare's TYK2 Inhibitor Phase III Success" event impact InnoCare Pharma?

Accepted Answer

InnoCare Pharma is the developer of fadeucravacitinib; the positive Phase III results enhance its drug pipeline and prospects for regulatory approval, positively impacting its valuation.

Question 11

How did the "InnoCare Orelabrutinib Mesutoclax BTD China" event impact InnoCare Pharma?

Accepted Answer

InnoCare is the developer of the combination therapy and the recipient of the BTD, which is a significant regulatory milestone that could accelerate clinical development and commercialization, positively impacting its pipeline and market position.

Question 12

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.